Insulet Uniquely Positioned With Omnipod 5 Insulin Pump – Milestone With Quarterly Revenue Exceeding $600 Million!

Insulet (PODD) is positioned uniquely as a leading insulin pump provider, with its Omnipod 5, which has been approved for Type 1 diabetics in the USA for the past three years, already reaching 365,000 of a total of 500,000 active customers. A year ago, the approval was also expanded to Type 2 diabetics, where acceptance is also accelerating. This is the only and first FDA-approved automated insulin delivery system (AID) for Type 1 and Type 2 diabetics that is tubeless and waterproof. Thanks to advanced algorithms, adults can reportedly increase...